Compare · MMM vs PLSE
MMM vs PLSE
Side-by-side comparison of 3M Company (MMM) and Pulse Biosciences Inc (PLSE): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MMM and PLSE operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- MMM is the larger of the two at $80.20B, about 45.7x PLSE ($1.75B).
- Over the past year, MMM is up 6.6% and PLSE is up 46.6% - PLSE leads by 40.0 points.
- Both names hit the wire about 2 times in the past 4 weeks.
- MMM has more recent analyst coverage (25 ratings vs 6 for PLSE).
- Company
- 3M Company
- Pulse Biosciences Inc
- Price
- $153.78+0.65%
- $25.38-5.70%
- Market cap
- $80.20B
- $1.75B
- 1M return
- +4.91%
- +31.74%
- 1Y return
- +6.64%
- +46.62%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 2016
- News (4w)
- 2
- 2
- Recent ratings
- 25
- 6
3M Company
3M Company develops, manufactures, and markets various products worldwide. It operates through four business segments: Safety and Industrial, Transportation and Electronics, Health Care, and Consumer. The Safety and Industrial segment offers personal safety products, industrial adhesives and tapes, abrasives, closure and masking systems, electrical markets, automotive aftermarket, and roofing granules to industrial, electrical, and safety markets. The Transportation and Electronics provides electronics, such as display materials and systems, electronic materials solutions; automotive and aerospace, and commercial solutions; advanced materials; and transportation safety products to transportation and electronic original equipment manufacturer customers. The Health Care segment offers medical and surgical supplies, skin health and infection prevention products, oral care, separation and purification sciences, health information systems, drug delivery systems, and food safety products to healthcare industry. The Consumer segment provides home improvement, home care, and consumer health care products, as well as stationery and office supplies to various consumers. This segment is also involved in the retail auto care business. It offers its products through various e-commerce and traditional wholesalers, retailers, jobbers, distributors, and dealers, as well as directly to users. 3M Company has a strategic collaboration with Merry Maids in residential cleaning sector; and collaborations with The Infectious Disease Research Institute and Duke Human Vaccine Institute to create a vaccine candidate with potential to provide protection against multiple variants of SARS-CoV-2. The company was founded in 1902 and is headquartered in St. Paul, Minnesota.
Pulse Biosciences Inc
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue primarily for dermatology applications by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Latest MMM
- SEC Form SD filed by 3M Company
- 3M Announces Upcoming Investor Event
- 3M Company filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Sweet Thomas W was granted 1,360 shares (SEC Form 4)
- Director Kereere Suzan was granted 1,360 shares, increasing direct ownership by 27% to 6,422 units (SEC Form 4)
- Director Fitterling James R was granted 1,360 shares (SEC Form 4)
- Director Brown Thomas K was granted 1,360 shares (SEC Form 4)
- Director Chow Anne H was granted 1,360 shares (SEC Form 4)
- Director Choi Audrey was granted 1,360 shares (SEC Form 4)
- Director Bozeman David P was granted 1,360 shares (SEC Form 4)
Latest PLSE
- Canaccord Genuity initiated coverage on Pulse Biosciences with a new price target
- Pulse Biosciences to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
- Amendment: Director Duggan Robert W bought $12,999,988 worth of shares (660,233 units at $19.69), increasing direct ownership by 1% to 48,370,047 units (SEC Form 4)
- SEC Form 10-Q filed by Pulse Biosciences Inc
- Amendment: SEC Form SCHEDULE 13D/A filed by Pulse Biosciences Inc
- ATM Equity Purchases by Pulse Biosciences' Co-Chairmen Total Approximately $13.3 Million
- Amendment: Chief Executive Officer Laviolette Paul A bought $295,350 worth of shares (15,000 units at $19.69), increasing direct ownership by 1,773% to 15,846 units (SEC Form 4)
- Chief Executive Officer Laviolette Paul A bought $295,350 worth of shares (15,000 units at $19.69) (SEC Form 4)
- Director Duggan Robert W bought $12,999,988 worth of shares (660,233 units at $19.69), increasing direct ownership by 1% to 48,211,433 units (SEC Form 4)
- SEC Form DEF 14A filed by Pulse Biosciences Inc